110 related articles for article (PubMed ID: 20371132)
21. Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways.
Li M; Jung A; Ganswindt U; Marini P; Friedl A; Daniel PT; Lauber K; Jendrossek V; Belka C
Biochem Pharmacol; 2010 Jan; 79(2):122-9. PubMed ID: 19686703
[TBL] [Abstract][Full Text] [Related]
22. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
[TBL] [Abstract][Full Text] [Related]
23. Development and biological evaluation of a novel aurora A kinase inhibitor.
Sardon T; Cottin T; Xu J; Giannis A; Vernos I
Chembiochem; 2009 Feb; 10(3):464-78. PubMed ID: 19199284
[TBL] [Abstract][Full Text] [Related]
24. Aurora kinase inhibitors as anti-cancer therapy.
Lok W; Klein RQ; Saif MW
Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
[TBL] [Abstract][Full Text] [Related]
25. Phosphorylation of histone H3 serine 10 in early mouse embryos: active phosphorylation at late S phase and differential effects of ZM447439 on first two embryonic mitoses.
Teperek-Tkacz M; Meglicki M; Pasternak M; Kubiak JZ; Borsuk E
Cell Cycle; 2010 Dec; 9(23):4674-87. PubMed ID: 21099354
[TBL] [Abstract][Full Text] [Related]
26. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
[TBL] [Abstract][Full Text] [Related]
27. Reactivity of integrin-linked kinase in human mesothelial cell proliferation.
Watzka SB; Setinek U; Huber M; Cantonati H; Lax F; Watson S; Weigel G; Müller MR
Interact Cardiovasc Thorac Surg; 2008 Feb; 7(1):107-10. PubMed ID: 18048409
[TBL] [Abstract][Full Text] [Related]
28. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
Evans RP; Naber C; Steffler T; Checkland T; Maxwell CA; Keats JJ; Belch AR; Pilarski LM; Lai R; Reiman T
Br J Haematol; 2008 Feb; 140(3):295-302. PubMed ID: 18076711
[TBL] [Abstract][Full Text] [Related]
29. Aurora-A kinase phosphorylation of Aurora-A kinase interacting protein (AIP) and stabilization of the enzyme-substrate complex.
Katayama H; Sasai K; Czerniak BA; Carter JL; Sen S
J Cell Biochem; 2007 Dec; 102(5):1318-31. PubMed ID: 17957726
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.
Borges KS; Castro-Gamero AM; Moreno DA; da Silva Silveira V; Brassesco MS; de Paula Queiroz RG; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
J Cancer Res Clin Oncol; 2012 Mar; 138(3):405-14. PubMed ID: 22160182
[TBL] [Abstract][Full Text] [Related]
31. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
[TBL] [Abstract][Full Text] [Related]
32. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.
Adams ND; Adams JL; Burgess JL; Chaudhari AM; Copeland RA; Donatelli CA; Drewry DH; Fisher KE; Hamajima T; Hardwicke MA; Huffman WF; Koretke-Brown KK; Lai ZV; McDonald OB; Nakamura H; Newlander KA; Oleykowski CA; Parrish CA; Patrick DR; Plant R; Sarpong MA; Sasaki K; Schmidt SJ; Silva DJ; Sutton D; Tang J; Thompson CS; Tummino PJ; Wang JC; Xiang H; Yang J; Dhanak D
J Med Chem; 2010 May; 53(10):3973-4001. PubMed ID: 20420387
[TBL] [Abstract][Full Text] [Related]
33. Neurotensin expression and outcome of malignant pleural mesothelioma.
Alifano M; Loi M; Camilleri-Broet S; Dupouy S; Régnard JF; Forgez P
Biochimie; 2010 Feb; 92(2):164-70. PubMed ID: 19932148
[TBL] [Abstract][Full Text] [Related]
34. Effects of DNAzymes targeting Aurora kinase A on the growth of human prostate cancer.
Qu Y; Zhang L; Mao M; Zhao F; Huang X; Yang C; Xiong Y; Mu D
Cancer Gene Ther; 2008 Aug; 15(8):517-25. PubMed ID: 18404163
[TBL] [Abstract][Full Text] [Related]
35. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation.
Chieffi P; Cozzolino L; Kisslinger A; Libertini S; Staibano S; Mansueto G; De Rosa G; Villacci A; Vitale M; Linardopoulos S; Portella G; Tramontano D
Prostate; 2006 Feb; 66(3):326-33. PubMed ID: 16267859
[TBL] [Abstract][Full Text] [Related]
36. Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.
Bosotti R; Carpinelli P; Healy S; Locatelli G; Cappella P; Lanfrancone L; Calogero R; Moll J; Isacchi A
Gene; 2012 Feb; 494(2):202-8. PubMed ID: 21914463
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition.
Vidarsdottir L; Steingrimsdottir G; Bodvarsdottir SK; Ogmundsdottir HM; Eyfjord JE
Invest New Drugs; 2012 Apr; 30(2):425-34. PubMed ID: 20960027
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Aurora Kinase A enhances chemosensitivity of medulloblastoma cell lines.
El-Sheikh A; Fan R; Birks D; Donson A; Foreman NK; Vibhakar R
Pediatr Blood Cancer; 2010 Jul; 55(1):35-41. PubMed ID: 20232424
[TBL] [Abstract][Full Text] [Related]
39. Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT.
Baldini E; Arlot-Bonnemains Y; Sorrenti S; Mian C; Pelizzo MR; De Antoni E; Palermo S; Morrone S; Barollo S; Nesca A; Moretti CG; D'Armiento M; Ulisse S
BMC Cancer; 2011 Sep; 11():411. PubMed ID: 21943074
[TBL] [Abstract][Full Text] [Related]
40. Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines.
León LG; Giovannetti E; Alecci C; Giancola F; Funel N; Zucali P; Peters GJ; Padrón JM
In Vivo; 2011; 25(2):203-7. PubMed ID: 21471536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
